Autonomic nervous system-dependent and -independent cardiovascular effects of exendin-4 infusion in conscious rats

British Journal of Pharmacology

Volumn 154, Issue 1, 2008, Pages 60-71

  Gardiner, S M ^a   March, J E ^a   Kemp, P A ^a   Bennett, T ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Exendin 4; Glucagon like peptide 1; Regional haemodynamics

Indexed keywords

ALPHA ADRENERGIC RECEPTOR; ANGIOTENSIN II; BETA ADRENERGIC RECEPTOR; ENDOTHELIN; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; NEUROPEPTIDE Y; PROSTANOID; VASOPRESSIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTONOMIC NERVOUS SYSTEM; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFECT; DRUG INFUSION; DRUG MECHANISM; HINDLIMB; MALE; MESENTERY BLOOD FLOW; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; SPRAGUE DAWLEY RAT; TACHYCARDIA; VASOCONSTRICTION;

EID: 42949089309     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/bjp.2008.75     Document Type: Article

References (36)

1. Barragán JM, Eng J, Rodríguez RE, Blázquez E (1999). Neural contribution to the effect of glucagon‐like peptide‐1‐(7‐36) amide on arterial blood pressure in rats. Am J Physiol 277: E784–E791.
2. Barragán JM, Rodríguez RE, Blázquez E (1994). Changes in arterial blood pressure and heart rate by glucagon‐like peptide‐1‐(7‐36) amide in rats. Am J Physiol 266: E459–E466.
3. Barragán JM, Rodríguez RE, Eng J, Blázquez E (1996). Interactions of exendin‐(9‐39) with the effects of glucagon‐like peptide‐1‐(7‐36) amide and of exendin‐4 on arterial blood pressure and heart rate in rats. Regul Pept 67: 63–68.
4. Batin P, Gardiner SM, Compton AM, Bennett T (1991). Differential regional hemodynamic effects of the non‐peptide angiotensin II antagonist, DuP 753, in water‐replete and water‐deprived Brattleboro rats. Life Sci 48: 733–739.
5. Blonde L, Klein EJ, Han J, Zhang B, Mac SM, Poon TH et al. (2006). Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 8: 436–447.
6. Bojanowska E, Stempniak B (2002). Effects of glucagon‐like peptide‐1 (7‐36) amide on neurohypophysial and cardiovascular functions under hypo‐ or normotensive hypovolaemia in the rat. J Endocrinol 172: 303–310.
7. Daniel EE, Anvari M, Fox‐Threlkeld JET, McDonald TJ (2002). Local, exendin‐(9‐39)‐insensitive, site of action of GLP‐1 in canine ileum. Am J Physiol 283: G595–G602.
8. Degn KB, Brock B, Juhl CB, Djurhuus CB, Grubert J, Kim D et al. (2004). Effect of intravenous infusion of exenatide (synthetic exendin‐4) on glucose‐dependent insulin secretion and counterregulation during hypoglycaemia. Diabetes 53: 2397–2403.
9. Gardiner SM, Bennett T (1985). Interactions between neural mechanisms, the renin–angiotensin system and vasopressin in the maintenance of blood pressure during water deprivation: studies in Long Evans and Brattleboro rats. Clin Sci 68: 647–657.
10. Gardiner SM, Bennett T (1988). Regional hemodynamic responses to adrenoceptor antagonism in conscious rats. Am J Physiol 255: H813–H824.
11. Gardiner SM, Compton AM, Bennett T (1989). Regional hemodynamic changes following hypovolemia in conscious rats. Am J Physiol 256: R1076–R1083.
12. Gardiner SM, Compton AM, Bennett T (1990). Effect of indomethacin on the regional haemodynamic responses to low doses of endothelins and sarafotoxin. Br J Pharmacol 100: 158–162.
13. Gardiner SM, March JE, Kemp PA, Bennett T (2006a). Mesenteric vasoconstriction and hindquarters vasodilatation accompany the pressor actions of exendin‐4 in conscious rats. J Pharmacol Exp Ther 316: 852–859.
14. Gardiner SM, March JE, Kemp PA, Bennett T (2006b). Effects of nitric oxide synthase inhibition with or without cyclooxygenase‐2 inhibition on resting haemodynamics and responses to exendin‐4. Br J Pharmacol 149: 802–809.
15. Gardiner SM, March JE, Kemp PA, Mullins JJ, Bennett T (1995). Haemodynamic effects of losartan and the endothelin antagonist, SB 209670, in conscious, transgenic ((mRen‐2)27), hypertensive rats. Br J Pharmacol 116: 2237–2244.
16. Göke R, Larsen PJ, Mikkelsen JD, Sheikh SP (1995). Distribution of GLP‐1 binding sites in the rat brain: evidence that exendin‐4 is a ligand of brain GLP‐1 binding sites. Eur J Neurosci 7: 2294–2300.
17. Golpon HA, Puechner A, Welte T, Wichert PV, Feddersen CO (2001). Vasorelaxant effect of glucagon‐like peptide‐(7‐36) amide and amylin on the pulmonary circulation of the rat. Regul Pept 102: 81–86.
18. Gotthardt M, Lalyko G, Van Eerd‐Vismale J, Keil B, Schurrat T, Hower M et al. (2006). A new technique for in vivo imaging of specific GLP‐1 binding sites: first results in small rodents. Regul Pept 137: 162–167.
19. Iltz JL, Baker DE, Setter SM, Campbell RK (2006). Exenatide: an incretin mimetic for the treatment of type 2 diabetes mellitus. Clin Ther 28: 652–665.
20. Kieffer TJ, Habener JF (1999). The glucagon‐like peptides. Endocr Rev 20: 876–913.
21. Knudsen LB (2004). Glucagon‐like peptide‐1: the basis of a new class of treatment for type 2 diabetes. J Med Chem 47: 4128–4134.
22. Malendowicz LK, Nowak KW (2002). Preproglucagon derived peptides and thyrotropin (TSH) secretion in the rat: robust and sustained lowering of blood TSH levels in exendin‐4 injected animals. Int J Mol Med 10: 327–331.
23. Malendowicz LK, Nowak KW, Zyterska A, Nussdorfer GG, Macchi C, Nowak M (2001). Exendin‐4, a GLP‐1 receptor agonist, stimulates entero‐insular axis in the rat, through a mechanism involving adrenal medulla. Biomed Res 22: 295–297.
24. Malendowicz LK, Nussdorfer GG, Nowak KW, Ziolkowska A, Tortorella C, Trejter M (2003). Exendin‐4, a GLP‐1 receptor agonist, stimulates pituitary–adrenocortical axis in the rat: investigations into the mechanism(s) underlying Ex4 effect. Int J Mol Med 12: 237–241.
25. Nielsen LL (2005). Incretin mimetics and DPP‐IV inhibitors for the treatment of type 2 diabetes. Drug Discov Today 10: 703–710.
26. Nielsen LL, Young AA, Parkes DG (2004). Pharmacology of exenatide (synthetic exendin‐4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept 117: 77–88.
27. Nishizawa M, Nakabayashi H, Kawai K, Ito T, Kawakami S, Nakagawa A et al. (2000). The hepatic vagal reception of intraportal GLP‐1 is via receptor different from the pancreatic GLP‐1 receptor. J Auton Nerv Syst 80: 14–21.
28. Nyström T, Gonon AT, Sjöholm Å, Pernow J (2005). Glucagon‐like peptide‐1 relaxes rat conduit arteries via an endothelium‐independent mechanism. Regul Pept 125: 173–177.
29. Parkes D, Jodka C, Smith P, Nayak S, Rinehart L, Gingerich R et al. (2001b). Pharmacokinetic actions of exendin‐4 in the rat: comparison with glucagon‐like peptide‐1. Drug Dev Res 53: 260–267.
30. Parkes DG, Pittner R, Jodka C, Smith P, Young A (2001a). Insulinotropic actions of exendin‐4 and glucagon‐like peptide‐1 in vivo and in vitro. Metabolism 50: 583–589.
31. Studer RK, Borle AB (1982). Differences between male and female rats in the regulation of hepatic glycogenolysis. The relative role of calcium and cAMP in phosphorylase activation by catecholamines. J Biol Chem 257: 7987–7993.
32. Theodorsson‐Norheim E (1987). Friedman and Quade tests: BASIC computer program to perform nonparametric two‐way analysis of variance and multiple comparisons on ranks of several related samples. Comput Biol Med 17: 85–99.
33. Woolard J, Bennett T, Dunn WR, Heal DJ, Aspley S, Gardiner SM (2004). Acute cardiovascular effects of sibutramine in conscious rats. J Pharmacol Exp Ther 308: 1102–1110.
34. Yamamoto H, Kishi T, Lee CE, Choi BJ, Fang H, Hollenberg AN et al. (2003). Glucagon‐like peptide‐1‐responsive catecholamine neurons in the area postrema link peripheral glucagon‐like peptide‐1 with central autonomic sites. J Neurosci 23: 2939–2946.
35. Yamamoto H, Lee CE, Marcus JN, Williams TD, Overton JM, Lopez ME et al. (2002). Glucagon‐like peptide‐1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest 110: 43–52.
36. Zhang W, Lundberg JM, Thorén P (1999). The effect of a neuropeptide Y antagonist, BIBP 3226, on short‐term arterial pressure control in conscious unrestrained rats with congestive heart failure. Life Sci 65: 1839–1844.